Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Pharmacy and Therapeutics

• Publication date

  2007-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1365-2710.2007.00811.xPMID 17381666
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia

  2006cited by this paper
• Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers

  2005cited by this paper
• Risperidone plasma levels, clinical response and side–effects

  2005cited by this paper
• Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9‐hydroxyrisperidone in schizophrenic patients

  2005cited by this paper
• Therapeutic Monitoring of New Antipsychotic Drugs

  2004cited by this paper
• Effects of Various CYP2D6 Genotypes on the Steady-State Plasma Concentrations of Risperidone and Its Active Metabolite, 9-Hydroxyrisperidone, in Japanese Patients With Schizophrenia

  2003cited by this paper
• Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers

  2002cited by this paper
• Carbamazepine–Risperidone Interactions in Patients With Epilepsy

  2002cited by this paper
• Extrapyramidal Symptoms with Ritonavir/Indinavir Plus Risperidone

  2002cited by this paper
• Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes

  2002cited by this paper
• Reversible Coma Caused By Risperidone-Ritonavir Interaction

  2002cited by this paper
• Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients.

  2001cited by this paper
• Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit

  2001cited by this paper
• An Evaluation of Risperidone Drug Interactions

  2001cited by this paper
• Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate.

  2000cited by this paper
• Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection.

  2000cited by this paper
• Effect of Rifampin on Plasma Concentrations of Mefloquine in Healthy Volunteers

  2000cited by this paper
• The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron

  1999cited by this paper
• Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

  1999influential reference
• A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

  1999influential reference
• Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

  1999cited by this paper
• Risperidone-carbamazepine interactions: is cytochrome P450 3A involved?

  1998influential reference
• The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

  1997cited by this paper
• Triazolam is ineffective in patients taking rifampin

  1997cited by this paper
• Pharmacologic approach to management of agitation associated with dementia.

  1994cited by this paper
• The pharmacokinetics of risperidone in humans: a summary.

  1994cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Risperidone in the treatment of schizophrenia.

  1994cited by this paper
• Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects

  1993influential reference
• Absorption, metabolism, and excretion of risperidone in humans.

  1993cited by this paper
• Clinical review of risperidone.

  1993cited by this paper
• Pharmacokinetic Drug Interactions with Rifampicin

  1992cited by this paper
• Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

  1992cited by this paper

• Management of Pulmonary Tuberculosis in Patient with Schizophrenia

  2025cites this paper
• Pulmonary tuberculosis in diabetes: Exploring the intersection and impact on mental health

  2025cites this paper
• Rifampin – Risperidone and Divalproex Drug-drug Interaction: A Case Report

  2023cites this paper
• Interaction of drugs with gut microbiota modulators

  2023cites this paper
• Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone

  2022cites this paper
• Specificity of time- and dose-dependent morphological endpoints in the fish embryo acute toxicity (FET) test for substances with diverse modes of action: the search for a “fingerprint”

  2021cites this paper
• Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions.

  2021cites this paper
• Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir

  2020cites this paper
• How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

  2020cites this paper
• Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents

  2020cites this paper
• Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics

  2020cites this paper
• Cytochrome P450 (CYP450) Interactions Involving Atypical Antipsychotics Are Common in Community-Dwelling Older Adults Treated for Behavioral and Psychological Symptoms of Dementia

  2020influential citation
• Update of Antibiotic Therapy of Brucellosis

  2020cites this paper
• Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy

  2019cites this paper
• Drug-Drug and Food-Drug Interactions of Pharmacokinetic Nature

  2018cites this paper
• Targeted Differentiation of Pluripotent Stem Cells to Hepatocytes

  2018cites this paper
• ADME Processes in Pharmaceutical Sciences

  2018cites this paper
• Clinical and experimental research in antituberculosis drug-induced hepatotoxicity: a review.

  2017cites this paper
• Increasing serum transaminase is not associated with the serum isoniazid and rifampicin levels in tuberculosis patients treated with fixed-dose combination antituberculosis in Yogyakarta

  2017cites this paper
• Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction.

  2016cites this paper
• Identification of rifampin-regulated functional modules and related microRNAs in human hepatocytes based on the protein interaction network

  2016cites this paper
• Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug–drug interaction

  2015cites this paper
• Development, validation and application of the Basel phenotyping cocktail

  2015cites this paper
• Interakcje Olanzapiny, Risperidonu i Kwetiapiny z lekami stosowanymi w niektórych chorobach somatycznych - część II Interaction Olanzapine, Risperidone and Quetiapine with drugs used in certain somatic diseases - Part II

  2015cites this paper
• Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults

  2015cites this paper
• CYP3A5 regulates prostate cancer cell growth by facilitating nuclear translocation of AR

  2015cites this paper
• Naegleria fowleri: Pathogenesis, Diagnosis, and Treatment Options

  2015cites this paper
• Characterization of risperidone-induced weight gain mediated by alterations of the gut microbiome and suppression of host energy expenditure

  2015cites this paper
• Optimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatment

  2015cites this paper
• Evaluation of Potential Pharmacokinetic Drug-Drug Interaction Between Armodafinil and Risperidone in Healthy Adults

  2015cites this paper
• Design and applications of bioprecursors: a retrometabolic approach.

  2014cites this paper
• Lurasidone drug-drug interaction studies: a comprehensive review

  2014cites this paper
• 2808 – A Review of the Interplay Between Tuberculosis and Mental Health

  2013cites this paper
• Update on rifampin, rifabutin, and rifapentine drug interactions

  2013cites this paper
• Pharmacogenetics of clinical response to risperidone.

  2013cites this paper
• Pharmacogenomics can improve antipsychotic treatment in schizophrenia

  2013cites this paper
• Influence of Rifampicin on the Pharmacokinetics of Salvianolic Acid B May Involve Inhibition of Organic Anion Transporting Polypeptide (Oatp) Mediated Influx

  2012cites this paper
• Preclinical study of a potent P-glycoprotein and cytochrome P450 enzyme inducer rifampicin changing pharmacokinetic parameters of risperidone and its metabolite, 9-hydroxyrisperidone, using a rat model

  2012cites this paper
• Autism Treatment Evaluation Checklist

  2012cites this paper
• Cytochrome P 450 2 D 6 Genotyping Potential Role in Improving Treatment Outcomes in Psychiatric Disorders

  2012influential citation
• Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers

  2012cites this paper
• Metabolism of Psychotropic Drugs

  2012cites this paper
• Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams

  2011cites this paper
• Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides.

  2011cites this paper
• Cytochrome P450 2D6 Genotyping

  2009cites this paper
• CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.

  2009cites this paper
• The effects of pharmacogenetics on pharmacokinetics of artemisinin-based combinations in malaria patients

  2009cites this paper
• Guía de actuación farmacéutica en pacientes con esquizofrenia

  2009cites this paper
• Current awareness in human psychopharmacology

  2008cites this paper
• ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety

  2008cites this paper
• EFFECT OF THE ENDOTHELIN RECEPTOR ANTAGONIST CPU0213, AND ITS MODULATION BY RIFAMPIN, ON CARDIAC AND VASCULAR TISSUE FOLLOWING CHRONIC ISOPROTERENOL TREATMENT

  2008cites this paper
• Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides.

  2004cites this paper
• Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides Keywords Rifaximin Pharmacokinetics Pharmacodynamics Toxicity Polymyxins Aminoglycoside Rifampin

  year unknowncites this paper